BidaskClub Upgrades Novavax (NVAX) to “Buy”

Novavax (NASDAQ:NVAX) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Wednesday.

Several other research analysts also recently commented on the company. JPMorgan Chase & Co. upgraded Novavax from an “underweight” rating to an “overweight” rating and lifted their price objective for the stock from $2.00 to $2.25 in a report on Friday, September 21st. Zacks Investment Research raised Novavax from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Tuesday, August 14th. B. Riley set a $10.00 target price on Novavax and gave the stock a “buy” rating in a research note on Monday, October 8th. Cantor Fitzgerald set a $2.00 target price on Novavax and gave the stock a “hold” rating in a research note on Wednesday, September 26th. Finally, Piper Jaffray Companies raised Novavax from a “neutral” rating to an “overweight” rating in a research note on Monday, November 26th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $3.36.

NVAX opened at $2.01 on Wednesday. The stock has a market capitalization of $777.19 million, a PE ratio of -3.19 and a beta of 2.49. Novavax has a 12 month low of $1.05 and a 12 month high of $2.75.



Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). The company had revenue of $7.70 million during the quarter, compared to analysts’ expectations of $9.63 million. The firm’s quarterly revenue was down 8.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.15) EPS. As a group, research analysts expect that Novavax will post -0.52 EPS for the current year.

A number of institutional investors have recently bought and sold shares of NVAX. Baker BROS. Advisors LP bought a new stake in Novavax during the 3rd quarter valued at approximately $8,870,000. Pictet Asset Management Ltd. bought a new stake in Novavax during the 3rd quarter valued at approximately $5,619,000. Vanguard Group Inc. boosted its position in Novavax by 6.1% during the 3rd quarter. Vanguard Group Inc. now owns 22,331,455 shares of the biopharmaceutical company’s stock valued at $41,982,000 after acquiring an additional 1,291,644 shares in the last quarter. Eagle Asset Management Inc. bought a new stake in Novavax during the 2nd quarter valued at approximately $1,675,000. Finally, Northern Trust Corp boosted its position in Novavax by 22.0% during the 2nd quarter. Northern Trust Corp now owns 4,429,972 shares of the biopharmaceutical company’s stock valued at $5,935,000 after acquiring an additional 797,965 shares in the last quarter. 40.87% of the stock is currently owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen.

Recommended Story: Call Option

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply